Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

This publication has 33 references indexed in Scilit:

• Prospective Comparison of Mammography, Sonography, and MRI in Patients Undergoing Neoadjuvant Chemotherapy for Palpable Breast Cancer
  American Journal of Roentgenology, 2005
• A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer
  Breast Cancer Research and Treatment, 2005
• HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer
  Clinical Cancer Research, 2004
• Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
  Journal of Clinical Oncology, 2004
• International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations
  Journal of Clinical Oncology, 2003
• Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera
  Oncogene, 2002
• Endocrine-responsive breast cancer and strategies for combating resistance
  Nature Reviews Cancer, 2002
• Activation of Estrogen Receptor ? by S118 Phosphorylation Involves a Ligand-Dependent Interaction with TFIIH and Participation of CDK7
  Molecular Cell, 2000
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• Evaluation of epidermal growth factor receptor occupency by EGF-like peptide in 55 breast and 42 non breast tumor biopsies
  European Journal of Cancer and Clinical Oncology, 1990